Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

(Bloomberg) -- Novo Nordisk A/S’s once-weekly insulin failed to get approval from ... daily injections and reduce waste from injection pens. In the US, about 1.7 million people have type 1 ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes ... company’s latest prefilled insulin pen, FlexTouch, which has an easy auto-injector mechanism.

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast ... we introduced the world’s first pen-shaped devices for subcutaneous injection in 1985.

Novo Nordisk A/S, together with its subsidiaries ... The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes ...